COVID-19

Sino Biologica has announced a co-development agreement with Nanommune, an Irvine, California-based biotechnology company specialising in the development and application of multiplex array technology. Under the terms of the agreement, the two companies will jointly develop coronavirus antigen array products for serological studies of COVID-19 and other infectious diseases. The two companies also debuted the […]

Sino Biological announced on April 1, that the company has received support from the Bill & Melinda Gates Foundation for the colloidal gold and ELISA based diagnosis of COVID-19. The fund will be used for the development of key antigen and antibody reagents needed for rapid and high throughput detection of SARS-CoV-2 (formerly 2019-nCoV). This […]

Mologic, developer of lateral flow and rapid diagnostic technologies, on March 26 announced that it has initiated early validation of COVID-19 point-of-need diagnostic tests with the Liverpool School of Tropical Medicine and St Georges’ University London. The availability of fast, reliable diagnostics for COVID-19 has been identified as one of the critical opportunities to support […]

Mologic has announced that it has launched an accelerated programme with the Institut Pasteur de Dakar, Senegal to develop a low-cost, high-performance rapid diagnostic test for Ebola Virus Disease (Ebola). The project is supported by the Wellcome Trust and the UK Government’s Department for International Development (DFID) through their joint call to advance epidemic preparedness. […]

PerkinElmer, announced on March 24 that the U.S. Food and Drug Administration (FDA) has provided emergency use authorisation (EUA) for the company’s new Coronavirus RT-PCR test. Clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA) can immediately begin using this kit to detect SARS-CoV-2, the virus that causes COVID-19. PerkinElmer’s RT-PCR test is marketed as an in-vitro […]